Company news
Prescient Therapeutics Limited (ASX:PTX) news
Prescient Therapeutics Limited news releases on 6ix. Latest, Nov 18, 2019: PTX in new CAR-T collaboration
Press releases — page 3
PTX in new CAR-T collaboration
November 17, 2019
1st patient dosed in trial for first in class drug PTX-100
November 13, 2019
Receipt of R&D Tax Rebate
November 7, 2019
Prescient Ausbiotech Ras Presentation
October 30, 2019
September 2019 Appendix 4C - Quarterly
October 29, 2019
Appendix 4E and 2019 Annual Report
August 25, 2019
June 2019 Appendix 4C - Quarterly
July 23, 2019
PTX Initiates Phase 1b Clinical Trial for PTX-100
July 10, 2019
Change to Exercise Price of Options
May 30, 2019
Canadian Patent Granted for PTX-200
May 15, 2019
Entitlement Offer Results and Shortfall Notification
April 26, 2019
March 2019 Appendix 4C - Quarterly
April 24, 2019
Despatch of Entitlement Offer Documents
April 3, 2019
Prospectus
March 24, 2019
December 2018 Appendix 4C - Quarterly
January 31, 2019
Interim Durability Analysis of PTX-200 Breast Cancer Study
December 9, 2018
September 2018 Appendix 4C - Quarterly
October 31, 2018
Pipeline Collaboration for Next Generation Formulations
October 16, 2018
Change of Registry Address: Automic P/L - Sydney Office
September 28, 2018
Improved manufacturing route for PTX-100
September 2, 2018
Appendix 4E and 2018 Annual Report
August 31, 2018
PTX-200 AML Study Expanded
August 29, 2018
June 2018 Appendix 4C - Quarterly
July 31, 2018
US Patent Granted for PTX-200 for Ovarian Cancer Treatment
July 25, 2018
March 2018 Appendix 4C - Quarterly
April 23, 2018
Response to Aware Query
April 11, 2018
PTX-200 Phase 1b Breast Cancer Trial Results
April 9, 2018
March 2018 Investor Presentation
March 18, 2018
December 2017 Appendix 4C - Quarterly
January 31, 2018
Clinical Trial Updates
January 28, 2018
Clinical Hold Lifted on PTX-200 Breast Cancer Trial
December 10, 2017
PTX to resume Clinical Trial of PTX-200 in Ovarian Cancer
November 5, 2017
September 2017 Appendix 4C - Quarterly
October 26, 2017
PTX-100 to Re-enter Trials in Hematology Niche
October 2, 2017
Prescient to resume AML trial
September 3, 2017
Appendix 4E and 2017 Annual Report
August 29, 2017
June 2017 Appendix 4C - Quarterly
July 25, 2017
Novel PTX-100 Cancer Approach Published in Nature
June 18, 2017
Clinical Trial Update
May 28, 2017
PTX Broker Presentation
May 16, 2017
European Patent Granted for PTX-200
May 11, 2017
Kansas University Joins PTXs AML Trial
May 7, 2017
FDA Grants Orphan Drug Designation for PTX-200 in AML
April 30, 2017
March 2017 Appendix 4C - Quarterly
April 27, 2017
Successful Completion of Phase 1b Breast Cancer Trial
April 6, 2017
Three Additional US Patents Granted
March 15, 2017
First Cohort Successfully Completed in Phase 1b/2 AML Trial
March 7, 2017
December 2016 Appendix 4C - Quarterly
January 24, 2017
First Patient Dosed on Phase 1b/2 AML Trial
December 13, 2016
Phase 1b/2 Ovarian Trial Commences 2nd Dose Escalation
December 8, 2016